Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.

[1]  J. Rygaard,et al.  Heterotransplantation of a human malignant tumour to "Nude" mice. , 2009, Acta pathologica et microbiologica Scandinavica.

[2]  B. Giovanella,et al.  Development of invasive tumors in the "nude" mouse after injection of cultured human melanoma cells. , 1972, Journal of the National Cancer Institute.

[3]  V. Courtenay,et al.  An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents. , 1978, British Journal of Cancer.

[4]  V. Courtenay,et al.  The response to chemotherapy of a variety of human tumour xenografts. , 1983, British Journal of Cancer.

[5]  R. Custer,et al.  A severe combined immunodeficiency mutation in the mouse , 1983, Nature.

[6]  G. Steel,et al.  Characterization of four new cell lines derived from human squamous carcinomas of the uterine cervix. , 1987, Cancer research.

[7]  K. Tonkin,et al.  Establishment and Response to Chemotherapy of Human Cervical Carcinoma Xenografts , 1988 .

[8]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[9]  J. Double,et al.  Therapeutic index: a vital component in selection of anticancer agents for clinical trial. , 1989, Journal of the National Cancer Institute.

[10]  G. Steel,et al.  A comparison of the in vivo and in vitro radiation response of three human cervix carcinomas. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  L. Kèlland,et al.  The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  L. Kèlland,et al.  Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. , 1993, British Journal of Cancer.

[13]  L. Kèlland,et al.  New platinum antitumor complexes. , 1993, Critical reviews in oncology/hematology.

[14]  M. Grever,et al.  Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. , 1994, Journal of the National Cancer Institute.

[15]  M R Grever,et al.  In vivo cultivation of tumor cells in hollow fibers. , 1995, Life sciences.

[16]  Melinda G. Hollingshead,et al.  Human Tumor Xenograft Models in NCI Drug Development , 1997 .

[17]  L. Kèlland,et al.  cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  P. Cooper,et al.  Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs. , 1998, Cancer research.

[19]  N. J. McNally,et al.  United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.

[20]  E. Sausville,et al.  Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  P. Beale,et al.  Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. , 1999, Journal of inorganic biochemistry.

[22]  T G Myers,et al.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.

[23]  L. Kèlland,et al.  Telomerase inhibitors: targeting the vulnerable end of cancer? , 2000, Anti-cancer drugs.

[24]  A. George,et al.  Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. , 2000, Cancer research.

[25]  P. Workman,et al.  Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone , 2000, Oncogene.

[26]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[27]  M. Gore,et al.  ZD0473 phase II monotherapy trial in second-line ovarian cancer , 2001 .

[28]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[29]  M. Dowsett,et al.  Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  H. Fiebig,et al.  Human Tumor Xenografts and Explants , 2002 .

[31]  S. Harrison.  Perspective on the History of Tumor Models , 2002 .

[32]  S. Eccles.  Models for Evaluation of Targeted Therapies of Metastatic Disease , 2002 .

[33]  S. Neidle,et al.  A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. , 2002, Molecular pharmacology.

[34]  Richard E. Moore,et al.  Transplantable Syngeneic Rodent Tumors , 2002 .

[35]  M. Cher,et al.  Persistence of human vascular endothelium in experimental human prostate cancer bone tumors , 2004, Clinical & Experimental Metastasis.

[36]  D Selwood.  Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval , 2004, British Journal of Cancer.

[37]  L. Kèlland,et al.  Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery , 2004, Cancer Chemotherapy and Pharmacology.